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Intrahepatic cholestasis (SCIC) is an uncommon but potentially fatal complication of sickle cell disease (SCD), with a high death
rate,observedmainlyinpatientswithhomozygoussicklecellanemia.Herein,wedescribe acaseofsevereSCICtreated successfully
with aggressive manual exchange transfusion (ET). The patient was admitted with enlarged liver and signs of hepatic failure, such
as hyperbilirubinemia and coagulopathy. There was no evidence of viral hepatitis or biliary obstruction. We performed several
sessions of ET in order to reduce the percentage of HbS to levels inferior to 30%, which was successfully accomplished. The
patient had a complete recovery of hepatic function. This case has shown that ET is an eﬀective treatment of SCIC and should be
introduced early on the onset of this severe complication.
1.Introduction
Acute sickle hepatic crisis, also known as intrahepatic
cholestasis (SCIC), is an uncommon but potentially fatal
complication of sickle cell disease (SCD), with a high
death rate, observed mainly in patients with homozygous
sickle cell anemia. Its presentation ranges from a benign
hyperbilirubinemia to a fulminant hepatic failure [1–3].
This syndrome is characterized by abdominal pain in
the upper right quadrant, enlarged liver, acholic or light
stools, marked hyperbilirubinemia, and variable elevation
of aminotransferases (AST and ALT) levels, but usually no
more than 1–3 times normal [4–6]. In more severe cases,
renal dysfunction and alteration of coagulation tests can
be observed [3].The diagnosis requires exclusion of viral
hepatitis and cholecystitis/choletithiasis. Treatment patterns
are not well established and range from supportive care to
exchange transfusion. However, early recognition of severe
cases and aggressive exchange transfusion of red blood cells
(RBCs) are considered crucial to attain a favorable outcome
[7–10]. Herein, we have reported a case of severe SCIC with
a favorable outcome after aggressive exchange transfusion of
RBC.
2.Case
A 41-year-old male patient with sickle cell anemia, and
no family history of SCD, was admitted to the emergency
ward of our institution due to upper right quadrant pain
in abdomen started a few hours before. Moreover, the
patient noted worsening of jaundice, choluria, and fatigue.
Physical exam demonstrated jaundice, right upper quadrant
tenderness, an enlarged liver as well as a distended abdomen.
The patient denied fever, diarrhea, or bleeding. There
were no signs of encephalopathy. He had a history of
recurrent pain crisis and was submitted to cholecystectomy
a few years before because of the presence of gallstones.
The abdominal ultrasonography showed hepatomegaly with2 Anemia
Table 1: Evolution of bilirubin, HbS percentage, and INR with
exchange transfusion (ET).
D1 of ET D5 of ET D10 of ET
Bilirubin level (mg/dL) 58.9 50.19 16.99
HbS percentage 88.40 34.20 9.75
INR 4.21 1.4 1.4
signs suggestive of chronic liver disease, a moderate ascitis,
and absence of gallbladder and of spleen. There were no
evidencesofdilatedextrahepaticbiliaryductsorobstruction.
The laboratory data on admission were total bilirubin
39mg/dL(directbilirubin21.4mg/dL),hemoglobinconcen-
tration (Hb) 6.0g/dL, hematocrit (Hct) 18%, white blood
cell (WBC) count 23,100/µL, platelet count 317,000/µL, ala-
nine aminotransferase (ALT) 76U/L, aspartate aminotrans-
ferase (AST) 210U/L, alkaline phosphatase 557U/L, gama-
glutamyltransferase (gama-GT) 127U/L, albumin 2.8g/dL,
INR1.6andpartial thromboplastintime(PTT)162,2s(ratio
6,19). The serology tests for hepatitis B and C and for
HIV were negative. The patient was submitted to aggressive
manual exchange transfusion of RBC, in order to reduce
the percentage of HbS to levels inferior to 30%. Thirty
milligrams of vitamin K were administered on the ﬁrst day
with no recovery of INR or PTT. Simple transfusion of fresh
frozen plasma was performed whenever the INR values were
higher than 2.0. Evolution of bilirubin levels, hemoglobin S
(HbS) percentage and INR is shown in Figure 1 and Table 1.
3.Discussion
In this paper we report one case of intrahepatic cholesta-
sis, which is a rare but potentially fatal complication of
sickle cell disease. Its etiology remains unknown, but it is
believedthatthedeformederythrocytesadheretothehepatic
vascular endothelium resulting in sludging and congestion
of vascular beds, followed by tissue ischemia, infarction,
and liver dysfunction in the more severe cases. Moreover,
SCIC can superimpose on a liver with chronic disease due
to hemochromatosis and hepatitis.
Ahn and colleagues [11]r e p o r t e d7c a s e sf r o mt h e i r
institutionandanother37casesfromtheliteraturepublished
between1953and2002.The authorsclassiﬁed thepatientsin
2 groups according to disease severity. Group I patients pre-
sented a total bilirubin level of 27.6mg/dL and no evidence
ofseverehepaticdysfunction, whereas patientsfromgroupII
presented a mean bilirubin of 76.8mg/dL and signs of severe
hepatic dysfunction, manifested by prolonged coagulation
tests(PTandPTT)and/orencephalopathy.Overallmortality
was 4% in group I and 64% in group II. However, only
2 of 9 who were submitted to RBC exchange transfusion
died, whereas 12 of 13 who did not receive transfusion died.
This result indicates that exchange transfusion is the basis
of SCIC treatment as suggested by previous studies [12–
14]. In the case described here the diagnosis of SCIC was
suspected because the sudden hyperbilirubinemia associated
with a modest elevation of aminotransferases and severe
liver dysfunction manifested by coagulopathy. Viral hepatitis
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Figure 1: Exchange transfusion and evolution of bilirubin levels,
hemoglobin S (HbS) percentage and INR according to the day of
hospital admission.
can present a similar clinical feature, however elevated
transferases is a frequent ﬁnding, sometimes with values
higher than 1000U/L. Furthermore, positive serology helps
to deﬁne viral hepatitis. Another potentially confounding
hepaticconditionishepaticsequestrationthatpresenttender
hepatomegaly associated with decrease in Hb concentration
and reticulocytosis, a mild to moderate increase in amino
transferases, but not extreme hyperbilirubinemia. The so-
called hepatic crisis is another hepatic condition considered
in the diﬀerential diagnosis of SCIC. It is characterized
by tender hepatomegaly, increasing jaundice, a mild to
moderate elevation of amino transferases, but the bilirubin
concentration seldom exceeds 13mg/dL. The case described
here presented clinical features suggestive of SCIC, and we
performed aggressive manual RBC exchange transfusions
aiming a decrease of HbS to levels below 30%, which was
successfully accomplished. The patient presented a favorable
evolution,and his hepatic function recovered to the previous
pattern. Currently, the patient is maintained in a scheme
of chronic RBC transfusion. This case reinforces the need
of performing ET for intrahepatic cholestasis treatment and
should be initiated promptly.
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